TABLE I.

Characteristics of enrolled subjects

Subject no.	Age (y)	Sex	Total IgE (kU/L)	Milk-specific IgE (kUA/L)	Milk skin test wheal (mm)/ erythema (mm)	Organ systems involved simultaneously in last historical reaction to milk (subjects had clinical reactivity to both cooked and uncooked milk products)*	Omalizumab dose and frequency	Total doses of omalizumab
1	11	M	500	42	25/50	Urticaria, angioedema, vomiting	225 mg every 2 wk	9
2	8	M	342	50	45/50	Wheezing, urticaria	225 mg every 4 wk	5
3	8	M	148	73	20/45	Urticaria, wheezing	150 mg every 4 wk	5
4	10	F	900	42	11/30	Vomiting, congestion	225 mg every 4 wk	5
5	8	M	239	50	46/52	Vomiting, generalized urticaria	225 every 2 wk	9
6	7	F	297	44	16/49	Wheezing, vomiting, urticaria	150 mg every 4 wk	5
7	12	M	199	68	15/50	Wheezing, urticaria, allergic rhinitis	150 mg every 4 wk	4
8	16	M	349	56	20/20	Wheezing, urticaria, abdominal complaints	225 mg every 2 wk	12
9	17	M	364	43	16/58	Wheezing, urticaria, conjunctivitis	300 mg every 2 wk	9
10	8	F	2016	268	24/46	Wheezing, vomiting, urticaria, conjunctivitis	300 mg every 2 wk	8
11	7	F	2593	342	16/22	Wheezing, urticaria, conjunctivitis	300mg every 2 wk	9
Median	8		349	50	20/50	Not applicable	Not applicable	8

Entry criteria: children 4 to 18 years of age with cow’s milk–specific IgE >25 kUA/L, total IgE <2500 kU/L; with significant clinical history of IgE mediated cow’s milk allergy, but without history of intubation, severe asthma, or previous immunotherapy or biologic therapy, and without a medical diagnosis of non–IgE-mediated eosinophilic disease.

F, Female; M, male.

^*None of the subjects had a diagnosis of eosinophilic esophagitis at screening and during the course of the study.